OPKO Health and Entera Bio have entered into a collaboration agreement to develop the first oral dual agonist GLP-1/glucagon peptide tablet for treating obesity and metabolic disorders. Key details include:
The program combines OPKO's long-acting oxyntomodulin analog (OPK-88006) with Entera's N-Tab oral delivery technology.
OPKO will have a 60% ownership stake and Entera will have a 40% stake in the program, with corresponding cost-sharing responsibilities.
OPKO purchased 3,685,226 Entera shares at $2.17 per share to fund Entera's Phase 1 development costs.
After Phase 1, Entera can maintain its 40% stake by continuing funding, or opt-out to retain 15% ownership while OPKO increases to 85%.
Favorable pharmacodynamic, pharmacokinetic and bioavailability data was reported in September 2024.
The companies plan to file an Investigational New Drug application with the FDA later in 2025.
This would be the first oral dual GLP-1/glucagon agonist to enter clinical development.
The treatment aims to suppress appetite, induce weight loss, and provide cardioprotective and anti-fibrotic benefits.
Currently, there are no approved dual GLP-1/glucagon agonists available on the market.
This collaboration represents a significant step in developing a potentially first-in-class oral therapy for obesity and metabolic disorders, combining OPKO's peptide expertise with Entera's oral delivery technology.